Just registered the 1,400,000th view of my blog site. So grateful for the support!
Last 12 posts going back to 28th June – feel free to read and share. Each one has a share button for Facebook, Twitter, Pinterest, WhatsApp and Email (as has the entire post).
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
Peptide Receptor Radionuclide Therapy (PRRT) has been around for a while and doctors are learning all the time about the most likely candidates. Selection of
Whenever I post about a new trial or study, some people get excited without understanding that these new treatments and capabilities can very often take
With Neuroendocrine Cancer patients, the mention of “diarrhea” is a topical subject. There’s the usual claim that it’s caused by carcinoid syndrome and for some
177Lu-DOTA-LM3 – a novel radionuclide therapy proven safe and effective to treat neuroendocrine neoplasms (NEN)
This is all the information available and further details to follow if any is published. Remember, this is not yet an approved treatment, nor is
It’s known that Neuroendocrine Cancer is quite different in many ways from other cancers, notwithstanding the misnomer term carcinoid which is thankfully being slowly moved
(so called) Carcinoid Crisis is one thing that tends to raise concerns in patients and has been bubbling away in NET centres and in patient
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)
Some of the key differences between Lanreotide and Octreotide long-acting are:1. Octreotide long-acting needs constituting prior to administration – Lanreotide comes prefilled. 2. Octreotide long-acting